Table 2. Patient demographics according to the presence/absence of sarcopenia.
| Variables | Sarcopenia (n=11) | Non-sarcopenia (n=36) | P-value | |
|---|---|---|---|---|
| Age (yr)* | 69.3±9.1 | 67.1±10.4 | 0.534 | |
| Sex | 0.023 | |||
| Male | 4 | 28 | ||
| Female | 7 | 8 | ||
| Tumor site | 0.924 | |||
| Body | 5 | 18 | ||
| Antrum | 5 | 14 | ||
| Esophagogastric junction (Siewert III) | 1 | 4 | ||
| Histology | 0.111 | |||
| Intestinal | 6 | 27 | ||
| Diffuse | 5 | 6 | ||
| Mixed | 0 | 3 | ||
| Clinical TNM stage | 0.322 | |||
| II | 0 | 5 | ||
| III | 11 | 31 | ||
| Type of ChT used | 0.388 | |||
| ECF/EOF/EOX/ECX | 2/0/6/0 | 9/2/17/1 | ||
| XELOX/FOLFOX/Xeloda/DCF | 1/0/1/1 | 6/1/0/0 | ||
| ChT response | 1.000 | |||
| Yes | 7 | 22 | ||
| No | 4 | 14 | ||
| ChT toxicity | ||||
| Grade 2/3/4 | 3/6/0 | 11/14/0 | 0.455 | |
| Type: GI/hematological/other | 5/2/3 | 12/12/4 | 0.135 | |
| DLT | 7 | 14 | 0.181 | |
| Early termination of ChT due to toxicity | 7 | 10 | 0.069 | |
| BMI(kg/m2) | 22.7±3.6 | 24.0±3.3 | 0.278 | |
| FMI(cm2/m2) | 39.1±34.0 | 53.9±36.7 | 0.241 | |
| MA (HU) | 31.2±7.4 | 35.1±8.0 | 0.151 | |
| Follow-up (mo)† | 10 [6–36] | 20 [9.25–33.75] | 0.551 | |
TNM = tumor, node, and metastasis; ChT = chemotherapy; ECF = epirubicin, cisplatin, and 5-fluorouracil; EOF = epirubicin, oxaliplatin, and 5-fluorouracil; EOX = epirubicin, oxaliplatin, and capecitabine; ECX = epirubicin, cisplatin, and capecitabine; XELOX = capecitabine plus oxaliplatin; FOLFOX = folinic acid plus 5-fluorouracil plus oxaliplatin; Xeloda = capecitabine; DCF = docetaxel, cisplatin, and 5-fluorouracil; GI = gastrointestinal; DLT = dose-limiting toxicity; BMI = body mass index; FMI = fat mass index; MA = muscle radiation attenuation; HU = Hounsfield unit; SD = standard deviation; IQR = interquartile range.
Values are presented differently follow as *mean±SD; †median [IQR].